The Lancet1d
The challenges of detecting early efficacy signals in lymphoma trials
Follicular lymphoma is considered an indolent disease, with long-term tumour control achieved by first-line ...
snmjournals.org1d
Molecular Imaging of Cancer Stem Cells and Their Role in Therapy Resistance
Despite recent therapeutic breakthroughs, cancer patients continue to face high recurrence and mortality rates due to treatment resistance. Cancer stem cells (CSCs), a subpopulation with self-renewal ...
Cure Today2d
CAR T-Cell Therapy Yescarta Continues to Demonstrate Durable Responses in Follicular Lymphoma
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma.
The American Journal of Managed Care2d
New Generation of CAR T May Elicit Improved CR Rates in CLL
T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic ...
Too Old to Operate2d
ZUMA-5: Curative Potential of Axi-Cel in Follicular Lymphoma
Axicabtagene ciloleucel had durable responses, long-term survival, and consistent outcomes in patients with relapsed or ...
I Was Diagnosed With Stage 4 Hodgkin’s Lymphoma In My 20s: What Are the Unusual Signs Of the Cancer the Youngster Ignored?
A young British woman who was hit with a devastating stage four cancer diagnosis in her late twenties explains how she ...
eLife6d
Synergistic effect of inhibiting CHK2 and DNA replication on cancer cell growth
By inhibiting the DNA polymerases, BKC enhances the endogenous RS in cancer cells, leading to increased DNA damage. IBC specifically inhibits CHK2 to prevent DNA repair. The combined use of BKC and ...